Given the seemingly constant failure of emerging disease-modifying therapies (DMTs) in Alzheimer's disease (AD) that target the amyloid cascade, industry has gradually expanded its focus to…
The development of biosimilar versions of Lucentis and Eylea is of high interest in the ophthalmology market given the high cost of these agents, the large patient population suffering from retinal…
The development of biosimilar versions of Lucentis and Eylea is of high interest in the ophthalmology market given the high cost of these agents, the large patient population suffering from retinal…
Instructions for uploading your PowerPoint presentation and survey: The PPT attachment needs to be the first node under the report (i.e., it should appear before your survey).Name the PPT in the…
Numerous drugs from multiple drug classes are used as monotherapies and/or adjunctive therapies for the treatment of major depressive disorder (MDD). The MDD treatment armamentarium is becoming…
Numerous drugs from multiple drug classes are used as monotherapies and/or adjunctive therapies for the treatment of major depressive disorder (MDD). The MDD treatment armamentarium is becoming…
The most highly anticipated analgesic drugs in late-phase development belong to the anti-nerve growth factor (NGF) class: Pfizer / Eli Lilly’s tanezumab and Regeneron / Teva / Mitsubishi Tanabe…
Dyslipidemia is an important modifiable risk factor for cardiovascular disease, which is one of the leading causes of death globally. Statins continue to dominate treatment of dyslipidemia, driven…
DED is one of the most common ocular conditions in the United States and Europe. Inflammation plays a prominent role in the pathogenesis of DED, and the condition may eventually lead to damage to…
Research on the human microbiome is beginning to mature, with microbiome-based therapies reaching the clinical trial phase of development for many disease areas. There have been significant…
Atopic dermatitis (AD) disproportionately affects children and adolescents, and its intermittent flares of itchy rash profoundly affect their quality of life. Most pediatric patients use prescribed…
Following the 2017 launches of two atopic dermatitis novel therapies, Pfizer’s topical PDE-4 inhibitor Eucrisa (crisaborole) and Sanofi/Regeneron’s IL-4/13 inhibitor Dupixent (dupilumab), the U…
Following the 2017 launches of two atopic dermatitis novel therapies, Pfizer’s topical PDE-4 inhibitor Eucrisa (crisaborole) and Sanofi/Regeneron’s IL-4/13 inhibitor Dupixent (dupilumab), the U…
The multiple sclerosis (MS) therapy market comprises more than a dozen disease-modifying therapies (DMTs) spanning a range of mechanisms of action, clinical profiles, formulations, and value…
No novel pharmacotherapeutics have entered the AD market in more than 15 years, despite a perennially full pipeline. However, the potential launches of the first disease-modifying therapies (DMTs)…